These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 26602294)

  • 1. Airway administration of a highly versatile peptide-based liposomal construct for local and distant antitumoral vaccination.
    Kakhi Z; Frisch B; Bourel-Bonnet L; Hemmerlé J; Pons F; Heurtault B
    Int J Pharm; 2015 Dec; 496(2):1047-56. PubMed ID: 26602294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal constructs for antitumoral vaccination by the nasal route.
    Kakhi Z; Frisch B; Heurtault B; Pons F
    Biochimie; 2016 Nov; 130():14-22. PubMed ID: 27423321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
    Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
    Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.
    Roth A; Rohrbach F; Weth R; Frisch B; Schuber F; Wels WS
    Br J Cancer; 2005 Apr; 92(8):1421-9. PubMed ID: 15812545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model.
    Razazan A; Behravan J; Arab A; Barati N; Arabi L; Gholizadeh Z; Hatamipour M; Reza Nikpoor A; Momtazi-Borojeni AA; Mosaffa F; Ghahremani MH; Jaafari MR
    PLoS One; 2017; 12(10):e0185099. PubMed ID: 29045460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
    Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
    Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity.
    Heurtault B; Gentine P; Thomann JS; Baehr C; Frisch B; Pons F
    Pharm Res; 2009 Feb; 26(2):276-85. PubMed ID: 18781377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines.
    van Slooten ML; Storm G; Zoephel A; Küpcü Z; Boerman O; Crommelin DJ; Wagner E; Kircheis R
    Pharm Res; 2000 Jan; 17(1):42-8. PubMed ID: 10714607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of peptide-based cancer vaccine compositions, by sequential screening, using versatile liposomal platform.
    Jacoberger-Foissac C; Saliba H; Seguin C; Brion A; Kakhi Z; Frisch B; Fournel S; Heurtault B
    Int J Pharm; 2019 May; 562():342-350. PubMed ID: 30880104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer.
    Farzad N; Barati N; Momtazi-Borojeni AA; Yazdani M; Arab A; Razazan A; Shariat S; Mansourian M; Abbasi A; Saberi Z; Badiee A; Jalali SA; Jaafari MR
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):665-673. PubMed ID: 30829072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect.
    Faham A; Altin JG
    J Immunol; 2010 Aug; 185(3):1744-54. PubMed ID: 20610649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.
    Burkhardt UE; Sloots A; Jakobi V; Wei WZ; Cavallo F; Kloke BP; Wels WS
    Cancer Immunol Immunother; 2012 Sep; 61(9):1473-84. PubMed ID: 22331080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following peroral administration route.
    Ge W; Li Y; Li ZS; Zhang SH; Sun YJ; Hu PZ; Wang XM; Huang Y; Si SY; Zhang XM; Sui YF
    Cancer Immunol Immunother; 2009 Feb; 58(2):201-8. PubMed ID: 18523770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
    Mansourian M; Badiee A; Jalali SA; Shariat S; Yazdani M; Amin M; Jaafari MR
    Immunol Lett; 2014 Nov; 162(1 Pt A):87-93. PubMed ID: 25086399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
    J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.